Publications
Publications
- Instant Pot for antigen retrieval: a simple, safe and economical method for use in immunohistochemistry.; BioTechniques. 2023 May 18.
- A Protease Activatable Interleukin-2 Fusion Protein Engenders Antitumor Immune Responses by Interferon Gamma-Dependent and Interferon Gamma-Independent Mechanisms.; Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research; Vol 42(7), pp. 316-328. 2022 Jul.
- Editorial: The Present and Future of Immunology Education.; Frontiers in immunology; Vol 12. 2021.
- Development of an Interleukin-12 Fusion Protein That Is Activated by Cleavage with Matrix Metalloproteinase 9.; Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research. 2019 Mar 08.
- Inoculating a New Generation: Immunology in Medical Education.; Frontiers in immunology; Vol 10. 2019.
- Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy.; Oncoimmunology; Vol 5(5). 2016 May.
- Characterization of an IL-12 p40/p35 Truncated Fusion Protein That can Inhibit the Action of IL-12.; Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research; Vol 35(9). 2015 Sep.
- Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints.; Nature communications; Vol 6. 2015.
- Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.; Expert review of clinical immunology; Vol 10(2). 2014 Feb.
- Generation of a dual-functioning antitumor immune response in the peritoneal cavity.; The American journal of pathology; Vol 183(4). 2013 Oct.
- IFN-γ mediates the antitumor effects of radiation therapy in a murine colon tumor.; The American journal of pathology; Vol 182(6). 2013 Jun.
- Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy.; Immunology; Vol 138(3). 2013 Mar.
- Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model.; Cancer immunity; Vol 13. 2013.
- A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens.; Journal of immunological methods; Vol 373(1-2). 2011 Oct 28.
- Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases.; Immunology; Vol 133(2). 2011 Jun.
- Identification of T-cell epitopes in Francisella tularensis using an ordered protein array of serological targets.; Immunology; Vol 132(3). 2011 Mar.
- A broadly applicable approach to T cell epitope identification: Application to improving tumor associated epitopes and identifying epitopes in complex pathogens; Journal of Immunological Methods (in press). 2011 Jan 01.
- IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms.; Journal of immunology (Baltimore, Md. : 1950); Vol 184(4). 2010 Feb 15.
- An approach to the identification of T cell epitopes in the genomic era: application to Francisella tularensis.; Immunologic research; Vol 45(2-3). 2009 Dec.
- Identification of a dominant CD4 T cell epitope in the membrane lipoprotein Tul4 from Francisella tularensis LVS.; Molecular immunology; Vol 46(8-9). 2009 May.
- Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity.; Journal of immunology (Baltimore, Md. : 1950); Vol 180(5). 2008 Mar 1.
- Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo.; Vaccine; Vol 25(17). 2007 Apr 30.
- Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag.; Vaccine; Vol 25(9). 2007 Feb 19.
- Spatial and temporal expression of herpes simplex virus type 1 amplicon-encoded genes: implications for their use as immunization vectors.; Human gene therapy; Vol 18(2). 2007 Feb.
- In vivo study of T-cell responses to skin alloantigens in Xenopus using a novel whole-mount immunohistology method.; Transplantation; Vol 83(2). 2007 Jan 27.
- Photodynamic therapy mediates the oxygen-independent activation of hypoxia-inducible factor 1alpha.; Molecular cancer therapeutics; Vol 5(12). 2006 Dec.
- Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth.; The American journal of pathology; Vol 169(5). 2006 Nov.
- Quorum sensing: dynamic response of Pseudomonas aeruginosa to external signals.; Trends in microbiology; Vol 14(2). 2006 Feb.
- Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.; Journal of immunology (Baltimore, Md. : 1950); Vol 174(12). 2005 Jun 15.
- Characterization of a lymph node within the mouse prostate: Detailed analysis using whole mount histology.; The Prostate; Vol 63(2). 2005 May 1.
- Imaging enzyme activity with polarization-sensitive confocal fluorescence microscopy.; Journal of microscopy; Vol 215(Pt 1). 2004 Jul.
- Activation of heat shock protein 70 promoter with meso-tetrahydroxyphenyl chlorin photodynamic therapy reported by green fluorescent protein in vitro and in vivo.; Photochemistry and photobiology; Vol 78(6). 2003 Dec.
- Transfection of the genes for interleukin-12 into the K1735 melanoma and the EMT6 mammary sarcoma murine cell lines reveals distinct mechanisms of antitumor activity.; International journal of cancer; Vol 106(5). 2003 Sep 20.
- Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts.; British journal of cancer; Vol 88(9). 2003 May 6.
- Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors.; The Prostate; Vol 51(3). 2002 May 15.
- In vitro assay for site-specific proteases using bead-attached GFP substrate.; BioTechniques; Vol 31(5). 2001 Nov.
- Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice.; Human gene therapy; Vol 12(15). 2001 Oct 10.
- T-cell antigen discovery (T-CAD) assay: a novel technique for identifying T cell epitopes.; Journal of immunological methods; Vol 256(1-2). 2001 Oct 1.
- Tumours can act as adjuvants for humoral immunity.; Immunology; Vol 102(4). 2001 Apr.
- Epitope mapping of human herpesvirus-7 gp65 using monoclonal antibodies.; Archives of virology; Vol 146(9). 2001.
- In vivo behavior of peptide-specific T cells during mucosal tolerance induction: antigen introduced through the mucosa of the conjunctiva elicits prolonged antigen-specific T cell priming followed by anergy.; Journal of immunology (Baltimore, Md. : 1950); Vol 164(9). 2000 May 01.
- Alteration of tumour response to radiation by interleukin-2 gene transfer.; British journal of cancer; Vol 82(4). 2000 Feb.
- Growth of human tumor xenografts in SCID mice quantified using an immunoassay for tumor marker protein in serum.; Journal of immunological methods; Vol 233(1-2). 2000 Jan 13.
- Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth.; Journal of immunology (Baltimore, Md. : 1950); Vol 162(11). 1999 Jun 1.
- Interleukin-3 and granulocyte-macrophage colony-stimulating factor enhance the generation and function of dendritic cells.; Immunology; Vol 97(1). 1999 May.
- The Roman god Janus: a paradigm for the function of CD43.; Immunology today; Vol 19(12). 1998 Dec.
- Regulation of human prostate-specific antigen gene expression in transgenic mice: evidence for an enhancer between the PSA and human glandular kallikrein-1 genes.; International journal of molecular medicine; Vol 2(4). 1998 Oct.
- IL-3 enhances both presentation of exogenous particulate antigen in association with class I major histocompatibility antigen and generation of primary tumor-specific cytolytic T lymphocytes.; Journal of immunology (Baltimore, Md. : 1950); Vol 160(12). 1998 Jun 15.
- IL-3-mediated enhancement of particulate antigen presentation by macrophages.; Journal of immunotherapy (Hagerstown, Md. : 1997); Vol 21(3). 1998 May.
- Tumor immunotherapy: cytokines and antigen presentation.; Cancer immunology, immunotherapy : CII; Vol 46(2). 1998 Apr.
- Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment.; Cancer research; Vol 58(7). 1998 Apr 1.
- A transgenic strategy for analyzing the regulatory regions of the human prostate-specific antigen gene: potential applications for the treatment of prostate cancer (Review).; International journal of molecular medicine; Vol 1(2). 1998 Feb.
- Expression of mouse CD43 in the B cell lineage of transgenic mice causes impaired immune responses to T-independent antigens.; European journal of immunology; Vol 27(9). 1997 Sep.
- Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy.; Proceedings of the National Academy of Sciences of the United States of America; Vol 94(12). 1997 Jun 10.
- Anti-CD43 inhibition of T cell homing.; The Journal of experimental medicine; Vol 185(8). 1997 Apr 21.
- Disregulated expression of CD43 (leukosialin, sialophorin) in the B cell lineage leads to immunodeficiency.; Journal of immunology (Baltimore, Md. : 1950); Vol 157(11). 1996 Dec 1.
- Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes.; Cancer immunology, immunotherapy : CII; Vol 42(6). 1996 Jul.
- Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells.; Proceedings of the National Academy of Sciences of the United States of America; Vol 93(8). 1996 Apr 16.
- Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor.; Cellular immunology; Vol 165(2). 1995 Oct 15.
- B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma.; Cellular immunology; Vol 165(2). 1995 Oct 15.
- Synergistic effects of co-expression of the TH1 cytokines IL-2 and IFN-gamma on generation of murine tumor-reactive cytotoxic cells.; International journal of cancer; Vol 61(5). 1995 May 29.
- Disregulation of leukosialin (CD43, Ly48, sialophorin) expression in the B-cell lineage of transgenic mice increases splenic B-cell number and survival.; Proceedings of the National Academy of Sciences of the United States of America; Vol 92(2). 1995 Jan 17.
- Transfection of transforming growth factor-beta producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytes.; Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy; Vol 15(3). 1994 Apr.
- Isolation and expansion of tumor-infiltrating lymphocytes.; BioTechniques; Vol 15(6). 1993 Dec.
- Interleukin-3 inhibits the generation of nonspecific killers by interleukin-2.; Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy; Vol 14(4). 1993 Nov.
- Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism.; Cancer research; Vol 53(9). 1993 May 1.
- Thy 1+ dendritic epidermal cells but not Langerhans cells express Ly 48.; The Journal of investigative dermatology; Vol 100(3). 1993 Mar.
- Differential epitope expression of Ly-48 (mouse leukosialin).; Immunogenetics; Vol 37(3). 1993.
- CD4-class II major histocompatibility complex interaction does not enhance killing by a class I-restricted CD4+CD8+ cytotoxic T cell clone.; European journal of immunology; Vol 22(9). 1992 Sep.
- Two regions of the H-2 Dd promoter are responsive to dimethylsulfoxide in line 1 cells by a mechanism distinct from IFN-gamma.; Journal of immunology (Baltimore, Md. : 1950); Vol 148(4). 1992 Feb 15.
- CD43 is expressed normally on Wiskott-Aldrich-derived lymphocytes.; Experimental and clinical immunogenetics; Vol 9(3). 1992.
- Mechanism of cytolytic T lymphocyte killing of a low class I-expressing tumor.; Journal of immunology (Baltimore, Md. : 1950); Vol 147(4). 1991 Aug 15.
- Class-I MHC expression in the mouse lung carcinoma, line 1: a model for class-I inducible tumors.; International journal of cancer. Supplement = Journal international du cancer. Supplement; Vol 6. 1991.
- The nucleotide sequence of Ly 48 (mouse leukosialin, sialophorin): the mouse homolog of CD43.; Nucleic acids research; Vol 18(16). 1990 Aug 25.
- Differential expression of interleukin 1 alpha by Thy-1+ and Thy-1- lung fibroblast subpopulations: enhancement of interleukin 1 alpha production by tumor necrosis factor-alpha.; European journal of immunology; Vol 20(8). 1990 Aug.
- CD43 (leukosialin, sialophorin, large sialoglycoprotein) can be expressed in both normal and Wiskott-Aldrich fibroblasts via transfection of a leukosialin cDNA.; European journal of immunology; Vol 20(7). 1990 Jul.
- Alteration of the metastatic potential of line 1 lung carcinoma cells: opposite effects of class I antigen induction by interferons versus DMSO or gene transfection.; Cellular immunology; Vol 127(2). 1990 May.
- cDNA cloning and localization of the mouse leukosialin gene (Ly48) to chromosome 7.; Immunogenetics; Vol 31(5-6). 1990.
- Characterization of cDNAs encoding human leukosialin and localization of the leukosialin gene to chromosome 16.; Proceedings of the National Academy of Sciences of the United States of America; Vol 86(4). 1989 Feb.
- Molecular analysis of deficient class I H-2 antigen expression by mouse lung carcinoma cells.; Journal of immunology (Baltimore, Md. : 1950); Vol 140(11). 1988 Jun 1.
- Lysis of a lung carcinoma by poly I:C-induced natural killer cells is independent of the expression of class I histocompatibility antigens.; Journal of immunology (Baltimore, Md. : 1950); Vol 140(7). 1988 Apr 1.
- Identification and characterization of a mouse cell surface antigen with alternative molecular forms.; Immunogenetics; Vol 28(5). 1988.
- Reduced tumorigenicity of a spontaneous mouse lung carcinoma following H-2 gene transfection.; Proceedings of the National Academy of Sciences of the United States of America; Vol 84(13). 1987 Jul.
- Identical RT1 class II molecules are expressed by rat RT1m and RT1c haplotypes.; Journal of immunology (Baltimore, Md. : 1950); Vol 135(4). 1985 Oct.
- An analysis of monoclonal T cell and antibody recognition sites on Ia molecules.; The Journal of investigative dermatology; Vol 85(1 Suppl). 1985 Jul.
- Clonotypic antibodies which stimulate T cell clone proliferation.; Immunological reviews; Vol 81. 1984 Oct.
- Multiple functional sites on a single Ia molecule defined using T cell clones and antibodies with chain-determined specificity.; The Journal of experimental medicine; Vol 159(3). 1984 Mar 1.
- T-lymphocyte clones.; Annual review of immunology; Vol 1. 1983.
- T cell clones specific for hybrid I-A molecules. Discrimination with monoclonal anti-I-Ak antibodies.; The Journal of experimental medicine; Vol 156(4). 1982 Oct 1.
- A pseudogene homologous to mouse transplantation antigens: transplantation antigens are encoded by eight exons that correlate with protein domains.; Cell; Vol 25(3). 1981 Sep.
- Analyses of RT1 products using two-dimensional polyacrylamide gels.; Transplantation proceedings; Vol 13(2). 1981 Jun.
- Serologic and biochemical analyses of rat class II molecules with anti-Ia sera.; Transplantation proceedings; Vol 13(2). 1981 Jun.
- Three cDNA clones encoding mouse transplantation antigens: homology to immunoglobulin genes.; Cell; Vol 24(1). 1981 Apr.
- Peptide map comparisons of epidermal and spleen H-2 molecules.; Immunogenetics; Vol 12(5-6). 1981 Mar 1.
- Serological and biochemical characterization of rat (RT1) class II molecules with restricted mouse anti-Ia sera.; Immunogenetics; Vol 13(1-2). 1981.
- Bone marrow origin of Ia molecules purified from epidermal cells.; The Journal of investigative dermatology; Vol 75(1). 1980 Jul.
- Structure of Ia antigens from the rat. Mouse alloantisera demonstrate at least two distinct molecular species.; European journal of immunology; Vol 10(2). 1980 Feb.
- Mouse epidermal Ia molecules have a bone marrow origin.; Nature; Vol 282(5736). 1979 Nov 15.
- Effects of Chloramphenicol on the Circadian Rhythm of Neurospora crassa.; Plant physiology; Vol 58(4). 1976 Oct.